
Novartis’ Vanrafia receives FDA accelerated approval for rare kidney disease
Basel: Swiss pharmaceutical major Novartis announced that the US Food and Drug Administration (FDA) has granted accelerated approval to its kidney disease drug Vanrafia (atrasentan) for the treatment of adults with immunoglobulin A nephropathy (IgAN) who …